Longevity.

Longevity-motivated fasting is driven by the autophagy hypothesis: that periodic fasting activates cellular cleanup mechanisms (autophagy, mitophagy) that slow aging, reduce cancer risk, and extend healthspan. The animal data for this is compelling. The human data is early-stage and limited. This is consumer education on what we know, what we do not know, and what is being marketed beyond the evidence.

Autophagy is the process by which cells break down and recycle damaged components — misfolded proteins, dysfunctional mitochondria, and other cellular debris. In animal models, fasting reliably upregulates autophagy, and interventions that increase autophagy consistently extend lifespan. The 2016 Nobel Prize in Physiology or Medicine was awarded for research on autophagy mechanisms. In mice, caloric restriction and periodic fasting extend lifespan by 20 to 40 percent. This is robust, well-replicated, and genuinely exciting science.

Measuring autophagy in living humans is technically difficult. There is no validated, non-invasive biomarker for autophagy levels in humans. What we can measure are proxy markers — IGF-1 reduction, AMPK activation, mTOR suppression — and these do respond to fasting in humans. But the leap from 'fasting reduces IGF-1' to 'fasting extends human lifespan' is enormous and unproven. No human trial has demonstrated that fasting extends lifespan, because such a trial would take decades and has not been conducted.

Most longevity researchers who practice what they study use periodic fasting rather than daily time restriction. The most common protocol among this group is a quarterly FMD cycle (5 days of fasting-mimicking diet every 3 to 4 months) or an annual extended water fast of 3 to 5 days. The logic is to trigger the autophagy and cellular renewal pathways periodically without the risks of chronic caloric restriction. This is a reasonable extrapolation from the available data, but it is an extrapolation — not a proven protocol.

IGF-1 (insulin-like growth factor 1) is the biomarker most commonly cited in longevity-fasting discussions. Low IGF-1 is associated with reduced cancer risk in epidemiological studies, and fasting reliably reduces IGF-1 levels. However, IGF-1 is also critical for muscle maintenance, bone density, and immune function. Chronically low IGF-1 — from aggressive caloric restriction or excessive fasting — carries its own risks, particularly in adults over 65. The longevity-optimized range for IGF-1 is not zero — it is moderate — and achieving that requires periodic fasting, not chronic restriction.

The most common overstatement in longevity-fasting marketing is the conflation of animal data with human outcomes. 'Fasting activates autophagy' is true in both animals and humans. 'Fasting extends lifespan' is true in animals and unknown in humans. 'Fasting reverses aging' is not demonstrated in any species. A wellness practitioner or supplement company that markets fasting as 'anti-aging' is selling a hypothesis, not an established clinical outcome.

What biomarkers are you tracking — IGF-1, fasting glucose, CRP, lipid panel? Are you working with a physician who understands fasting physiology? What fasting protocol are you following, and how frequently? Are you at risk of excessive restriction — underweight, loss of muscle mass, bone density concerns? Is your fasting practice sustainable over years, or is it a burst of enthusiasm that will fade?